Benign Hepatocellular Tumors


Abbreviations

ANGPT

angiopoietin

b-HCA

β-catenin–activated HCA

b-IHCA

β-catenin–activated inflammatory HCA

CEUS

contrast-enhanced ultrasound

CRP

C-reactive protein

FNH

focal nodular hyperplasia

GS

glutamine synthetase

H&E

hematoxylin and eosin

HBP

hepatobiliary phase

HCA

hepatocellular adenoma

HCC

hepatocellular carcinoma

H-HCA

HNF1α-inactivated HCA

HNF1α

hepatocyte nuclear factor 1 alpha

IHCA

inflammatory HCA

IL-6

interleukin-6

LFABP

liver fatty acid binding protein

MODY3

maturity-onset diabetes of the young, type 3

MRI

magnetic resonance imaging

NASH

nonalcoholic steatohepatitis

NOS

not otherwise specified

SAA

serum amyloid A

STAT3

signal transducer and activator of transcription 3

TERT

telomerase reverse transcriptase

Benign hepatocellular lesions are composed of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA). Both tumors develop in normal liver but differ from each other in terms of pathogenesis, incidence, imaging, pathology, complications, and treatment (see Suggested Readings for review). FNH was first described by Edmondson. Wanless and colleagues proposed that FNH is not a true tumor but a hyperplastic response of hepatic parenchyma to a preexisting localized arterial spider-like malformation, which likely represents a developmental vascular anomaly. The association between oral contraceptives and HCA was suggested by Baum and associates in 1973; this conclusion was subsequently confirmed in several case-control studies.

Definitions and Synonyms

Focal Nodular Hyperplasia

A plethora of terms has been used in the past to designate this tumor, including hepatic pseudotumor , hamartoma , solitary hyperplastic nodule , lobar or focal cirrhosis , benign hepatoma, and even adenoma ; these terms have now been abandoned in favor of focal nodular hyperplasia , or FNH. The definition of FNH requires the presence of several key features: multiple, spherical aggregates of benign hepatocytes held together in a fibrous meshwork that radiates outward from a prominent scar containing aberrant variably sized vessels with eccentrically thickened walls, as well as a ductular reaction and inflammatory infiltrate at the interface between the fibrous bands and hepatocytic nodules. The presence of unusual features or absence of some key ones makes the pathologic diagnosis more difficult.

The term subtle FNH indicates an early, not well-developed lesion that lacks, at least partially, the major key features. Telangiectatic FNH is now an obsolete term because this lesion has been shown to be an HCA (see later). FNH-like lesion is a term used for nodules with some morphologic characteristics of FNH that arise in the context of cirrhosis, vascular disorders, or in the vicinity of other tumors. The term multiple FNH syndrome is used to indicate the association of multiple FNH with other pathologic manifestations in the liver and outside the liver; this poorly characterized entity awaits reevaluation apropos the genotype-phenotype classification of HCA described later. The same is true for progressive FNH and mixed tumors.

Additional information about FNH is presented in Table 32.1 .

Table 32.1
Focal Nodular Hyperplasia
Features of Tumor Nodule Features of Background Liver
  • Typical

    • Solitary; occasionally multiple

    • With or without macroscopic scar (central or not)

    • Subtle a

  • Atypical

    • With steatosis, focal or diffuse

    • With atypical cytologic features (ie, Mallory bodies; large cell dysplasia; cholestasis)

    • With areas of sinusoidal dilatation

  • Multiple FNH syndrome c

  • Association with other benign nodules; hemangioma, HCA (single, multiple, or adenomatosis)

FNH may occur in

  • Normal liver

  • Abnormal liver

    • Steatosis (mild, moderate, or severe)

    • Vascular disease b

Budd-Chiari
Hereditary hemorrhagic telangiectasia
Agenesis of the portal vein; arteriovenous shunt

  • Cirrhosis b

  • In the immediate vicinity of HCC d

FNH , Focal nodular hyperplasia; HCA , hepatocellular adenoma; HCC , hepatocellular carcinoma.

a Glutamine synthetase immunohistochemistry is extremely useful to confirm the diagnosis.

b Some of these nodules, often called FNH-like nodules, probably represent hyperarterialized regenerative nodules as they do not share the molecular characteristics of FNH.

c This syndrome (multiple FNH, vascular malformations of various organs, and neoplasia of the brain) needs further molecular characterization.

d HCC may be misinterpreted as a malignant transformation of FNH (or FNH-like nodule). Instead, FNH-like change represents parenchymal hyperplasia in response to neovascularization of adjacent HCC.

Hepatocellular Adenoma

The term hepatocellular adenoma , or HCA, is favored over others such as benign hepatoma, liver cell adenoma, and liver adenoma, which are sometimes used to designate this tumor. HCA is a benign tumor of hepatocytes characterized by arterial vascularization that occurs in a liver that may be steatotic in some instances but is otherwise normal. The tumor is usually solitary but may be multifocal and varies in size from 0.5 to 15 cm in diameter. It is not encapsulated and composed of cells that resemble normal hepatocytes and may be steatotic. HCA is characterized by the absence of mitosis, portal tracts, and bile ducts; however, biliary cells and ductules may be present in some cases. The lesions display varying degrees of steatosis, sinusoidal dilatation, and inflammation; the strong correlation of these morphologic phenotypes with recently characterized molecular changes in HCA has led to the identification of distinct subgroups of HCA and the formulation of a genotype-phenotype classification.

The definition of the term adenomatosis requires the presence of at least 10 HCAs and is based on the number of nodules detected by imaging studies; the latter may, however, miss small (micro) adenomas. The term is however often used inappropriately. Mixed adenoma-focal nodular hyperplasia , a confusing term, indicates a collision tumor between FNH and HCA.

Additional information about HCA can be found in Table 32.2 .

Table 32.2
Hepatocellular Adenoma
Features of Tumor Features of Background Liver
  • Typical (single, multiple, adenomatosis)

    • HNF1α inactivated (LFABP - ): usually diffusely steatotic

    • Inflammatory (SAA + , CRP + )

    • β-catenin activated (β-cat + , GS + )

    • With or without inflammatory characteristics

    • Without specific characteristics

  • Atypical

    • Entirely hemorrhagic and/or necrotic

    • With architectural remodeling (changes secondary to necrosis, hemorrhage)

    • Could mimic FNH (fibrotic bands, ductular reaction)

    • Cytologic abnormalities

    • Differential diagnosis with borderline tumor and well-differentiated HCC may be impossible, if there was no previous proof that the lesion was benign

    • Mallory bodies, bone marrow metaplasia

HCA may occur in

  • Normal liver

  • Abnormal liver

    • Steatosis a (NASH/cirrhosis)

    • Vascular disorders (Budd-Chiari, agenesis of the portal vein)

    • Metabolic disorders (eg, glycogenosis types I and III, galactosemia, β-thalassemia, tyrosinemia)

    • Cirrhosis

CRP , C-reactive protein; FNH , focal nodular hyperplasia; GS , glutamine synthetase; HCC , hepatocellular carcinoma; HNF1α , hepatocyte nuclear factor 1 alpha; LFABP , liver fatty acid binding protein; NASH , nonalcoholic steatohepatitis; SAA , serum amyloid A.

a Steatotic background, which may be severe, is increasingly observed in the context of obesity/diabetes type 2; NASH and cirrhosis, however, are rare. These HCAs are usually of the inflammatory subtype.

Incidence and Demographics

FNH has been reported in 0.6% to 3% of the general population and is observed 10 times more frequently than HCA in referral centers. It is the second most frequent benign liver tumor after hemangioma. FNH develops more frequently in women (male-to-female ratio, 1:8) between the ages of 20 and 50 years. An association with oral contraceptive use is unlikely; however, some studies suggest that their use may increase the size of the tumor.

In Western countries, HCAs are rare tumors that usually develop in women who use oral contraceptives. Diabetes and obesity are also risk factors, at least for some subtypes, as described later in the chapter. In addition, HCAs have been associated with androgenic-anabolic steroid use, glycogenosis types I and III, galactosemia, tyrosinemia, vascular diseases, familial polyposis coli, and β-thalassemia. These tumors seem to be rarer in Asian countries such as Japan, where oral contraceptives are not commonly used, in comparison with Western countries.

Clinical Manifestations

FNH, whether solitary or multiple, is usually discovered incidentally. When large, the tumors may present as an abdominal mass and may compress the vascular tree, the biliary tree, or adjacent organs such as the stomach. FNH does not bleed or undergo malignant transformation. Reported cases of malignant transformation probably represent FNH-like proliferation in response to tumor arterialization at the periphery of a true hepatocellular carcinoma (HCC).

The clinical presentation of HCA varies widely. Lesions may be discovered incidentally during abdominal imaging for an unrelated cause, inflammatory syndrome, or abnormal liver function tests. Alternatively, they may be noticed by the individual as a palpable mass. Symptomatic patients may present with pain in the right upper quadrant or epigastrium; this symptom is present in 25% to 50% of patients with HCA. Rupture and bleeding into the peritoneum present as acute abdominal pain and signs of shock such as hypotension, tachycardia, and diaphoresis. Hemoperitoneum occurs more frequently in patients taking high-dose contraceptives or during menses, pregnancy, and the early postpartum period (within 6 weeks). Tumors are more likely to bleed if they are larger than 4 to 5 cm or situated near the surface of the liver.

During its natural evolution, HCA may remain stable, increase in size, or regress. Regression is more frequently described in HCA related to androgenic-anabolic steroids and glycogenosis after hormone withdrawal or initiation of an appropriate alimentary regimen, respectively. Malignant transformation into HCC is considered to be extremely rare but has been consistently described; it is most often seen in HCA related to androgenic-anabolic steroid exposure or glycogenosis type I. In addition, tumors with β-catenin mutations have a higher risk of malignant transformation (see later).

Radiologic Features

Focal Nodular Hyperplasia

Distinction between FNH and other hypervascular liver lesions such as HCA, HCC, and hypervascular metastases is critical for appropriate management. Asymptomatic FNH requires no specific treatment whereas other hypervascular lesions need specific treatment and/or close follow up. In its “classic form” FNH can be easily diagnosed with cross-sectional contrast-enhanced imaging. Characteristic imaging features of FNH include lesional homogeneity, significant enhancement on the arterial phase with lack of washout during the portal venous and delayed phases, peripheral lobulation, and the presence of a central scar. Based on these criteria, cross-sectional contrast-enhanced imaging has a sensitivity and a specificity of 70% and 100%, respectively, for the diagnosis of FNH.

Ultrasonography and Contrast-Enhanced Ultrasound

The majority of FNH lesions are discovered during an ultrasound examination undertaken for abdominal pain. FNH is typically isoechogenic or slightly hypoechogenic to the surrounding liver parenchyma. The presence of a central arterial pedicle with low resistance index on a Doppler study greatly assists its diagnosis.

Contrast-enhanced ultrasound (CEUS) shows a characteristic pattern of hypervascularity in the arterial phase, centrifugal filling, and the presence of stellate arteries producing a ‘‘spoke wheel’’ sign. Sustained portal venous phase enhancement is seen in the delayed phase. However, CEUS may not show centrifugal filling and the stellate arteries in very large lesions ( Fig. 32.1 ).

Figure 32.1, Magnetic resonance imaging and contrast-enhanced ultrasonography features of a typical focal nodular hyperplasia. The lesion is located in left liver lobe. A, Slight hyperintensity on fat-suppressed T2-weighted imaging with hyperintensity of the central scar. B, Isointensity on fat-suppressed T1-weighted imaging with hypointensity of the central scar. C, Strong and homogeneous arterial enhancement in the arterial phase except central scar. D, The lesion appears in isosignal to the surrounding liver parenchyma with delayed enhancement of the central scar. E to H, Early arterial phase on contrast-enhanced sonography showing a nodule with typical centrifugal filling and stellate vascularity. H, Moderate persistent enhancement in the delayed phase.

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) has higher sensitivity and specificity for diagnosis of FNH than ultrasonography or computed tomography. The lesion is typically isointense or slightly hypointense on T1-weighted images and slightly hyperintense or isointense on T2-weighted images obtained by MRI; the central scar is typically hypointense on T1-weighted images and hyperintense on T2-weighted images. During the arterial phase of gadolinium-enhanced imaging, FNH demonstrates intense homogeneous enhancement except for the central scar. During the portal and delayed phase, FNH returns to isointensity or occasionally remains slightly hyperintense to the surrounding liver parenchyma, whereas the central scar shows delayed enhancement because of slow diffusion of contrast through the myxoid stroma (see Fig. 32.1 ).

However, sensitivity for diagnosis decreases if one of these imaging features is missing, for example, in the absence of central scar ( Fig. 32.2 ), or in the presence of additional findings such as fat deposition or sinusoidal distention ( Fig 32.3 ). In these cases, the use of CEUS and/or liver-specific MRI contrast agents is paramount for differentiating FNH from other lesions such as HCA (see the section later on differential diagnosis ).

Figure 32.2, Magnetic resonance imaging features of an atypical FNH, with a 4-cm lesion, located in segment VII. It has the same intensity as the surrounding parenchyma on both T1-weighted ( A ) and T2-weighted ( B ) imaging. There is strong arterial enhancement ( C ) with isointense signal in the portal venous phase ( D ). These findings are compatible with FNH, but a central scar is not visible. In this case, the use of specific hepatobiliary agent (gadobenate dimeglumine) is necessary to distinguish focal nodular hyperplasia (FNH) and hepatocellular adenoma; delayed phase T1-weighted imaging shows persistent enhancement of the lesion with hypointense central scar characteristic of FNH ( E ).

Figure 32.3, Magnetic resonance imaging features of focal nodular hyperplasia (FNH) with sinusoidal distension. A, Axial fat-suppressed T1-weighted image sequence shows a 55-mm-diameter heterogeneous nodule in the segment VII. B, Axial fat-suppressed T2-weighted image shows heterogeneity of the lesion with a large hyperintense central area not suggestive of focal nodular hyperplasia. Gadolinium-enhanced, fat-suppressed T1-weighted images in the arterial ( C ), portal venous ( D ) phase: strong arterial enhancement of the nodule and heterogeneously sustained enhancement in the portal venous phases. The areas with delayed enhancement are corresponding with the highly hyperintense areas in T2-weighted images, suggesting areas of sinusoidal congestion (misleading for an inflammatory adenoma).

Hepatocellular Adenoma

Diagnosis of HCA is often more difficult because imaging features encompass a variety of appearances. Imaging findings include fatty, necrotic, and hemorrhagic components, but a homogeneous hypervascular appearance may also be seen.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here